No Data
No Data
KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference
BofA Securities Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $22
Major Investment Alert: KalVista Pharmaceuticals Sees Significant Stock Purchase!
Needham Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $28
JMP Securities Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $19
JonesTrading Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $30